Schwannomatosis Panel
Use
This test is intended for individuals who have clinical or suspected diagnoses of schwannomatosis or NF2-related schwannomatosis. It is also suitable for individuals displaying features such as bilateral vestibular schwannomas accompanied by tinnitus, hearing loss, and balance dysfunction. Additionally, it is for individuals presenting NF2-like characteristics without bilateral vestibular schwannomas, as well as children with retinal hamartoma, optic nerve thickening, cortical wedge cataracts, or unexplained third cranial nerve palsy. It targets individuals who experience symptom onset from the second to fourth decades of life.
Special Instructions
Not provided.
Limitations
This test has not been cleared or approved by the FDA. Given the complexity of schwannomatosis and related conditions, the detection accuracy is highly reliant on genetic variability and clinical presentations. Results interpretation is confined to the genes analyzed.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
No genes
Gene
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided